Enlivex Ltd stock is traded at $1.20, with a volume of 7,136. It is down -4.76% in the last 24 hours and down -70.36% over the past month. Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Previous Close:
$1.26
Open:
$1.25
24h Volume:
7,136
Relative Volume:
0.13
Market Cap:
$1.84M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.05
EPS:
$25.48
Net Cash Flow:
-$31.80M
1W Performance:
-5.51%
1M Performance:
-70.36%
6M Performance:
-99.33%
1Y Performance:
-99.51%
1-Day Range:
$1.19$1.34
1-Week Range:
$1.18$1.41
52-Week Range:
$1.18$434.40
Enlivex Ltd Stock (ENLV) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS